Online inquiry

IVTScrip™ mRNA-Anti-TNFRSF10B, ABBV-621(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ1045MR)

This product GTTS-WQ1045MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets TNFRSF10B gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_003842.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 8795
UniProt ID O14763
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNFRSF10B, ABBV-621(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ1045MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ7058MR IVTScrip™ mRNA-Anti-VEGFA, Fab-12 variant Y0317(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA Fab-12 variant Y0317
GTTS-WQ2200MR IVTScrip™ mRNA-Anti-IL15RA, ALT-803(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ALT-803
GTTS-WQ1069MR IVTScrip™ mRNA-Anti-SLAMF7, ABBV-838(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ABBV-838
GTTS-WQ3570MR IVTScrip™ mRNA-Anti-LYPD3, BAY 1112623(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA BAY 1112623
GTTS-WQ7875MR IVTScrip™ mRNA-Anti-APCS, GSK-2398852(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA GSK-2398852
GTTS-WQ14220MR IVTScrip™ mRNA-Anti-C5, RG-6107(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA RG-6107
GTTS-WQ3883MR IVTScrip™ mRNA-Anti-PDCD1, BCD-100(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA BCD-100
GTTS-WQ13101MR IVTScrip™ mRNA-Anti-ACVRL1, PF-03446962(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA PF-03446962
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW